4 Western medicines and 1 Chinese patent medicine for the treatment of prostatic hyperplasia can inhibit prostatic hyperplasia and hypertrophy from different angles, relax bladder smooth muscle, and improve symptoms such as frequent urination, urgency, urinary incontinence, and difficulty urinating:
1. Tamsulosin sustained-release capsules
The drug is a specific antagonist of the adrenaline α1 receptor subtype α1A. Because the α receptors present in the urethra, bladder neck and prostate are mainly α1A receptors, the drug has a highly selective blocking effect on the urethra, bladder neck and prostate smooth muscle, so that the smooth muscle is relaxed and the urethral compression is reduced. It has significantly improved symptoms such as dysuria, frequent urination at night, and residual urine sensation caused by prostatic hyperplasia. It is 13 times more effective at inhibiting rising intraurethral pressure than it is at inhibiting vasodilatory blood pressure. Therefore, not only is the drug effective, but it can also reduce the chance of orthostatic hypotension after taking the drug. This drug reduces prostate pressure in the intraurethral pressure curve without affecting rhythmic bladder contraction and intravesical pressure curve. In addition, there are no significant interactions with other antihypertensive drugs. The drug has no first-dose effect, and the first dose does not need to be reduced or emphasized to be taken before bedtime.
Clinically, it is mainly used for the treatment of urination disorders caused by prostatic hyperplasia. It is suitable for mild and moderate patients and those who have not caused severe urination disorders, and should not take this medicine alone if severe urinary retention has occurred.
2. Finasteride tablets
The drug is a specific inhibitor of endolactone type II 5α reductase. Type II 5a reductase metabolizes testosterone into the more potent androgen dihydrotestosterone, which is dependent on prostate growth. The drug slowly forms a stable enzyme complex with type II 5a reductase, inhibits the conversion of peripheral testosterone into dihydrotestosterone, reduces the level of dihydrotestosterone in the blood, prostate, skin and other tissues, thereby inhibiting prostatic hyperplasia and improving the related clinical symptoms of benign prostatic hyperplasia. The drug has no affinity for androgen receptors. Patients with benign prostatic hyperplasia take this product orally 5mg daily for 4 years, which can reduce the concentration of dihydrotestosterone in the blood circulation by 70%, reduce the prostate volume by 20%, and reduce prostate-specific antigen by 50%. In addition, the hair follicles contain type II 5a reductase, which reduces the number of hair follicles in the scalp in the bald area of male baldness and increases dihydrotestosterone. Administration of the drug can reduce the concentration of dihydrotestosterone in the scalp and serum of these patients, thereby inhibiting the reduction of scalp hair follicles and reversing the process of hair loss.
Clinically: (1) for the treatment and control of benign prostatic hyperplasia and the prevention of urological events (reducing the risk of acute urinary retention; reduce the risk of requiring urinary resection of the prostate and prostatectomy); (2) Patients with prostatic hypertrophy (can shrink the hypertrophic prostate, improve urine flow and improve symptoms related to prostatic hyperplasia).
3. Solifena succinate new tablets
Solifenacin, a competitive muscarinic receptor antagonist, is more selective for the bladder than for the salivary glands. Muscarinic M3 receptors play an important role in a number of functions that are primarily mediated by cholinergics, including contraction of bladder smooth muscle and stimulation of salivation. Solifenacin inhibits detrusor hyperactivity by blocking muscarinic M3 receptors in bladder smooth muscle, regulates bladder contractility, and increases bladder volume. This relieves the symptoms of urge incontinence, urgency, and frequency associated with an overactive bladder. Clinical practice has shown that it can significantly reduce the frequency of urinary urgency and prolong the time from strong desire to urinate to excretion, thereby improving the occurrence of urge incontinence. The new generation of therapeutic drugs, represented by solifenacin, has reduced the concentration of drugs in the central nervous system and has better selectivity for M3 subtype receptors, improving tolerability.
It is clinically used for the treatment of urinary incontinence and/or urinary frequency and urgency in patients with overactive bladder.
4. Mirabegron sustained-release tablets
Miraberon, a selective β3-adrenergic receptor agonist, can relax the detrusor muscle of the bladder, increase the storage capacity and urination interval, does not affect bladder emptying, and reduces the occurrence of acute urinary retention.
Clinically, it is mainly used for the symptomatic treatment of urinary frequency, urgency and urge incontinence in adult patients with overactive bladder.
5. Saw Palmetto Fruit Extract Softgel
The drug belongs to the fruit extract of saw palmetto, which competitively inhibits the binding of dihydrotestosterone to prostate male hormone receptors by inhibiting the activity of 5α reductase, reducing the conversion of testosterone to dihydrotestosterone. Inhibits the binding of androgens to androgen receptors in prostate tissue, thereby shrinking hyperplastic prostate tissue. In addition, it can also inhibit the activity of cyclooxygenase and lipoxygenase, reduce the production of inflammatory mediators such as leukotrienes and prostaglandins, and thus play a non-specific anti-inflammatory effect. It also has adrenergic antagonism and calcium blocking effect, which can play a role in antispasmodic bladder smooth muscle.
Clinically, it is suitable for the early stage of benign prostatic hyperplasia to improve urinary frequency, urgency, and dysuria. #头条创作挑战赛#
